In a significant return to the ophthalmology space, Merck & Co. has agreed to acquire EyeBio for US$3 B. The acquisition is centered on EyeBio’s lead candidate, Restoret (EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). This acquisition marks a significant milestone for both companies, signalling Merck's commitment to innovation and expansion within the ophthalmology space.